Skip to content

Released May 7, 2026, after the close

10-Q filed May 7, 2026, 37 days after period end · 0001785530-26-000012

Q1 2026 · 10-Q
Revenue—
Net Income-$13.53MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.28N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$13,271,000N/M
Operating Cash Flow-$10,597,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Net Income-$13.53M-$18.09M-$16.19M-$11.98M
EPS Diluted-$0.28-$0.40-$0.39-$0.34

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR